Nano-Cap Equillium Shares Fall After Patchy Hair Loss Study Data
Equillium released topline data from its Phase 2 study of EQ101 in adult patients with alopecia areata, a disease that results in patchy hair loss.
Mid-Cap Firm Annexon’s Nerve Disorder Candidate Shows Promise In Pivotal Late-Stage Study
Annexon reports positive Phase 3 trial results for ANX005 in Guillain-Barré syndrome, showing significant improvements in disability, muscle strength, and ventilation duration.
Bristol Myers Squibb Announces Phase 3 Results Of Opdivo/Yervoy Combo In Liver Cancer Patients
Opdivo plus Yervoy combo shows significant survival benefits and higher response rates vs. lenvatinib/sorafenib in HCC.
What’s Going On With Viking Therapeutics Stock On Tuesday?
Viking Therapeutics reports promising 52-week data from its Phase 2b VOYAGE study on VK2809 for NASH.
Capricor Therapeutics Reports 3-Year Efficacy Results From HOPE-2 Open Label Extension Study Of CAP-1002 In DMD
--Results in Performance of the Upper Limb (PUL 2.0) Continue to Show Benefits in Skeletal Muscle Function After 3 Years of CAP-1002 Treatment (p< 0.001)-- --Stabilization in Left Ventricular Ejection Fraction
Cyclacel’s Fadraciclib Reports Efficacy In Patient-Derived Colorectal Cancer Models At The 2024 ASCO Annual Meeting
- Novel CDK2/9 inhibitor fadraciclib induces anaphase catastrophe, a novel cancer-specific mechanism of action -BERKELEY HEIGHTS, N.J., June 04, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc.
Equillium Announces Topline Data From Phase 2 Study Of EQ101 In Alopecia Areata; 20% Of All Subjects That Completed The 24-week Treatment Period Achieved SALT ≤ 20; EQ101 Was Well Tolerated In Subjects With Alopecia Areata With No Serious Adverse Event…
20% of all subjects that completed the 24-week treatment period achieved SALT ≤ 2029% of completed subjects with moderate to severe disease (baseline SALT 35 to <95) achieved SALT ≤ 20EQ101 was well tolerated in
Cue Biopharma Presents Updated Data From Phase 1 Trial of CUE-101 In Recurrent/Metastatic HPV+ Head And Neck Cancer At ASCO 2024
Overall response rate (ORR) of 46% and 12-month overall survival (OS) of 96% in first line (1L) recurrent/metastatic (R/M) HPV+ head and neck squamous cell carcinoma (HNSCC) treated with CUE-101 and
MangoRx Introduces “MOJO” Pharmaceutical Compounded Formula Featuring Enclomiphene Citrate And Pregnenolone For Treatment Of Low Testosterone And Male Hormone Imbalances; Sold Exclusively On MangoRx’s Website On A Subscription Basis At A Price Of $199…
MOJO to be offered as an Oral Dissolvable Tablet (ODT) marketed to younger male demographic as an alternative to PRIME Testosterone Replacement Therapy (TRT)Dallas, Texas, June 04, 2024 (GLOBE NEWSWIRE) --
Nano-Cap Spruce Biosciences Collaborates With HMNC Brain Health To Develop Treatment for Major Depressive Disorder
Spruce Biosciences collaborates with HMNC Brain Health to advance tildacerfont, a precision therapeutic for major depressive disorder, using the Cortibon Genetic Selection Tool.